Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by One Capital Management LLC

One Capital Management LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,486 shares of the biopharmaceutical company’s stock after purchasing an additional 310 shares during the period. One Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $8,894,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of REGN. Proficio Capital Partners LLC raised its holdings in shares of Regeneron Pharmaceuticals by 92,865.3% during the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after purchasing an additional 219,162 shares during the period. Worldquant Millennium Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $127,489,000. KBC Group NV increased its holdings in shares of Regeneron Pharmaceuticals by 296.7% in the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after acquiring an additional 102,198 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $65,180,000. Finally, Icon Wealth Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after acquiring an additional 75,569 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $687.15 on Thursday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $75.12 billion, a PE ratio of 17.95, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The company has a 50 day moving average price of $696.58 and a two-hundred day moving average price of $857.92. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the previous year, the company earned $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Bank of America restated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. TD Cowen dropped their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.